avaloinvestordeckseptemb。Katsuaki Maehara: Therapeutic development of 4th generation。Discovery of Potent and Wild-Type-Sparing Fourth-Generation。Novel EGFR inhibitor overcomes common resistances to NSCLC。「NEWエッセンシャル法医学」高取健彦 / 長尾正崇定価: ¥ 8800#高取健彦 #長尾正崇 #本 #自然/医療・薬学・健康